CYTOART | Precision Detection & Full-Process Solutions for Cell Therapy

Resources

Explore our latest research articles and industry analyses to stay ahead in the rapidly evolving biopharmaceutical landscape. From breakthrough therapies to regulatory developments, we deliver authoritative content to support your professional growth in this dynamic field.

News
Events
Blog
FAQs

CD8 VHH LinkedIn Article PBMC Correction Map

Purpose: These edits correct the interpretation of PBMC / CD3- signals. The key scientific point is that CD3- PBMC signals should not be automatically described as non-specific binding, because the CD3- compartment includes NK cells and subsets of human NK cells can express CD8.
2026/07/24

A significant milestone for Cytoart/BioSwan—and new opportunities for our partners.

Our core patents covering anti-idiotype antibodies for CAR-T detection have now been granted in both the United States and China, with the corresponding European patent expected to be granted soon.
2026/07/16

CytoArt to Exhibit at TRCCC Annual Meeting | Connect with Our Team for CAR-T Solutions

CytoArt will participate in the TRCCC (Translational Research Cancer Centers Consortium) conference, with team members Dee LaVigne and Stephen Haley stationed at our on-site booth.
2026/06/03

CytoArt Attends SITC Spring Scientific Conference Hosted in Tucson

CytoArt Co-Founder Frank Li participated in the SITC Spring Scientific Conference, which was locally held in Tucson, Arizona.
2026/06/03

CytoArt’s Anti-Idiotype & VHH Solutions to Be Showcased at AACR 2026 (Booth #803)

CytoArt’s core team travels from Tucson headquarters to San Diego for the AACR 2026 Annual Meeting, taking residence at Booth #803 during April 17–22.
2026/06/03

CytoArt to Exhibit at AACR 2026 in San Diego | Visit Us at Booth #803

CytoArt’s core team travels from Tucson headquarters to San Diego for the AACR 2026 Annual Meeting, taking residence at Booth #803 during April 17–22.
2026/06/03

CytoArt Team Member Dee Claims 2nd Place at AACR 2026 Charity 5K Run

CytoArt Key Account Director Dee LaVigne earned the second place in women’s group at the AACR 2026 annual 5K charity running event held in San Diego ahead of the conference opening.
2026/06/03

CytoArt Concludes AACR 2026 Exhibition in San Diego

CytoArt’s team wrapped up a six-day exhibition at AACR 2026 Annual Meeting held in San Diego, and returned to Tucson after on-site industry communication.
2026/06/03

Case Study: Custom Anti-Leu16 Anti-Idiotype Antibody for In Vivo CD20 CAR-T Detection

In 2025, a US-based biotechnology firm focused on in vivo CAR-T research adopted CD20 (Leu16 scFv) as their core preclinical benchmark model, applicable for both human and non-human primate (NHP) animal studies.
2026/06/03

CytoArt to Exhibit at ASGCT 2026 Boston | Booth #601 (May 11–15)

CytoArt is pleased to announce our participation at the ASGCT 2026 Annual Meeting in Boston, held May 11–15 at Booth #601.
2026/06/03
ABOUT
Company
CONTACT
FAQ
Free Sample Request
LEGAL
Terms and Conditions
Legal Notice and Disclaimer
Privacy Policy
SOCIAL MEDIA
Linkedln
X / Twitter

©2026 Cytoart. All Rights Reserved.